SavedAdd your journal

Journals / Düzce Tıp Fakültesi Dergisi / 2026 / Volume: 28 Issue: 2

Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV

Sengül Üçer(Ankara Training and Research Hospital)0000-0002-1764-3198
Pınar Gürkaynak(Ankara Training and Research Hospital)0000-0001-8863-8268
Uğur Emre Gümüş(Ankara Training and Research Hospital)0009-0009-4681-9568
Melek Sena Altun(Ankara Training and Research Hospital)0000-0002-5612-7305
Şerife Altun Demircan(Ankara Training and Research Hospital)0000-0002-9295-4578
Esra Kaya Kılıç(Ankara Training and Research Hospital)0000-0002-3270-4841
Cigdem Ataman Hatipoglu(Ankara Training and Research Hospital)0000-0002-1104-8232
Gunay Tuncer Ertem(Ankara Training and Research Hospital)0000-0001-8760-0030
Salih Cesur(Ankara Training and Research Hospital)0000-0003-4960-7375
Sami Kınıklı(Ankara Training and Research Hospital)0000-0002-9661-7851
Pages
—
Publication Date
2026-08-21
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Identifying the underlying causes of poor vaccination adherence and implementing strategies to improve compliance are essential in PLWH.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: People living with HIV (PLWH) face a heightened risk of acquiring hepatitis B virus (HBV) infection because these two viruses share common transmission pathways.
📊
Key Findings & Data:HIV/HBV coinfection is associated with accelerated liver disease progression.
💡
Conclusion & Impact:Identifying the underlying causes of poor vaccination adherence and implementing strategies to improve compliance are essential in PLWH.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hepatitis B vaccines · HIV · antibodies

Abstract

Aim: People living with HIV (PLWH) face a heightened risk of acquiring hepatitis B virus (HBV) infection because these two viruses share common transmission pathways. HIV/HBV coinfection is associated with accelerated liver disease progression. Consequently, hepatitis B vaccination is a critical preventive measure for PLWH. This study was designed to assess the serological response to hepatitis B vaccination in PLWH. Material and Methods: PLWH followed at the Infectious Diseases and Clinical Microbiology Clinic who were seronegative for HBsAg, anti-HBs, and anti-HBc IgG were retrospectively identified. Anti-HBs levels measured 1 month to 1 year after the final vaccine dose were assessed. Criteria associated with low response (anti-HBs titer: <100 mIU/mL) and high response (≥100 mIU/mL) were also evaluated. Results: A total of 54 patients were included in the final analysis. The median age was 43 (range, 22–80) years and 25.9% of the patients were female. Forty-nine patients (90.7%) had anti-HBs levels ≥10 mIU/mL. Anti-HBs levels ≥100 mIU/mL were observed in 10 (28.6%) patients who had received at least one double-dose vaccination versus 3 (15.8%) patients who had not (p=0.341), and in 18 (51.4%) patients with undetectable HIV RNA versus 5 (26.3%) patients with detectable HIV RNA (p=0.091), without reaching statistical significance. Conclusion: Adherence to the hepatitis B vaccination schedule was found to be suboptimal. Identifying the underlying causes of poor vaccination adherence and implementing strategies to improve compliance are essential in PLWH.

🔖

Cite This Article

Üçer, S., Gürkaynak, P., Gümüş, U. E., Altun, M. S., Demircan, Ş. A., Kılıç, E. K., Hatipoglu, C. A., Ertem, G. T., Cesur, S., Kınıklı, S. (2026). Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV. Düzce Tıp Fakültesi Dergisi, Volume: 28 Issue: 2. https://doi.org/10.18678/dtfd.1910893

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (26)

  1. Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A, et al. Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis. J Viral Hepat. 2020;27(3):294-315. doi:10.1111/jvh.13217.
  2. Peng A, Wang L, Waleed K, Qiu L, Tong X, Tu Z, et al. The prognosis characteristics of HIV/HBV co-infection after antiviral therapy: a comprehensive review. Infect Agent Cancer. 2026;21(1):15. doi:10.1186/s13027-025-00724-5.
  3. Xu M, Warner C, Duan X, Cheng Z, Jeyarajan AJ, Li W, et al. HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1α- and TGF-β1-dependent pathway. J Hepatol. 2024;80(6):868-81. doi:10.1016/j.jhep.2024.01.026.
  4. Kolakowska A, Marshall E, Krastinova E, Cros A, Duvivier C, Leroy P, et al. Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: A prospective study in outpatient clinics in the Paris region. Vaccine. 2024;42(17):3655-63. doi:10.1016/j.vaccine.2024.04.077.
  5. Garcia A, Vigil KJ, Taylor B, Kshirsagar O, Thamer M, Jain MK. Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change? J Viral Hepat. 2023;30(10):790-2. doi:10.1111/jvh.13868.
  6. Ambrosioni J, Levi LI, Alagaratnam J, Sempere A, Mastrangelo A, Paioni P, et al. Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025. HIV Med. 2026;27(1):18-32. doi:10.1111/hiv.70120.
  7. Tian Y, Hua W, Wu Y, Zhang T, Wang W, Wu H, et al. Immune response to Hepatitis B virus vaccine among people living with HIV: a meta-analysis. Front Immunol. 2021;12:745541. doi:10.3389/fimmu.2021.745541.
  8. Corcorran MA, Kim HN. Strategies for Hepatitis B virus prevention in people living with HIV. Curr HIV/AIDS Rep. 2023;20(6):451-7. doi:10.1007/s11904-023-00670-0.
  9. Ursenbach A, Séverac F, Chahard A, Alfaiate D, Bani-Sadr F, Hocqueloux L, et al. Hepatitis B surface antibody clearance after vaccination in people with HIV. Open Forum Infect Dis. 2025;13(1):ofaf754. doi:10.1093/ofid/ofaf754.
  10. Lopes VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, Schutten M, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine. 2013;31(7):1040-4. doi:10.1016/j.vaccine.2012.12.047.
  11. Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine. 2012;30(41):5973-7. doi:10.1016/j.vaccine.2012.07.028.
  12. Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One. 2013;8(11):e80409. doi:10.1371/journal.pone.0080409.
  13. Tengan FM, Abdala E, Nascimento M, Bernardo WM, Barone AA. Prevalence of hepatitis B in people living with HIV/AIDS in Latin America and the Caribbean: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):587. doi:10.1186/s12879-017-2695-z.
  14. Togan RM, Youa FI, Atoun RC, Bigma M, Konu RY, Sadio AJ, et al. Viral hepatitis B co-infection among people living with HIV: a national cross-sectional survey in Togo in 2023. BMC Infect Dis. 2025;25(1):1432. doi:10.1186/s12879-025-11822-5.
  15. Steedman NM, McMillan A. Hepatitis B testing and vaccination in patients recently diagnosed with HIV infection. Int J STD AIDS. 2008;19(2):83-4. doi:10.1258/ijsa.2007.007144.
  16. Sheikh D, Staggers KA, Carey J, Keitel WA, Atmar RL, El Sahly HM, et al. Delays in Hepatitis B immunization series completion in people with human immunodeficiency virus. Open Forum Infect Dis. 2023;10(11):ofad543. doi:10.1093/ofid/ofad543.
  17. Tedaldi EM, Baker RK, Moorman AC, Wood KC, Fuhrer J, McCabe RE, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis. 2004;38(10):1478-84. doi:10.1086/420740.
  18. Catherine FX, Piroth L. Hepatitis B virus vaccination in HIV-infected people: a review. Hum Vaccin Immunother. 2017;13(6):1-10. doi:10.1080/21645515.2016.1277844.
  19. Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012;12(12):966-76. doi:10.1016/S1473-3099(12)70243-8.
  20. Cornejo-Juárez P, Volkow-Fernández P, Escobedo-López K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramírez LE. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther. 2006;3:9. doi:10.1186/1742-6405-3-9.
  21. Khaimova R, Fischetti B, Cope R, Berkowitz L, Bakshi A. Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV. Vaccine. 2021;39(44):6529-34. doi:10.1016/j.vaccine.2021.09.050.
  22. Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2015;15(11):1283-91. doi:10.1016/S1473-3099(15)00220-0.
  23. Vargas JI, Jensen D, Martínez F, Sarmiento V, Peirano F, Acuña P, et al. Comparative efficacy of a high-dose vs standard-dose Hepatitis B revaccination schedule among patients with HIV: a randomized clinical trial. JAMA Netw Open. 2021;4(8):e2120929. doi:10.1001/jamanetworkopen.2021.20929.
  24. Lee JH, Hong S, Im JH, Lee JS, Baek JH, Kwon HY. Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients. Vaccine. 2020;38(24):3995-4000. doi:10.1016/j.vaccine.2020.04.022.
  25. Nie L, Hua W, Liu X, Pang X, Guo C, Zhang W, et al. Associated Factors and Immune Response to the Hepatitis B Vaccine with a Standard Schedule: A Prospective Study of People with HIV in China. Vaccines (Basel). 2023;11(5):921. doi:10.3390/vaccines11050921.
  26. Joshi SS, Davis RP, Ma MM, Tam E, Cooper CL, Ramji A, et al. Reduced immune responses to Hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD). NPJ Vaccines. 2021;6(1):9. doi:10.1038/s41541-020-00266-4.